WellGen Closer to Studying Anti-Obesity Ingredient
Functional food ingredients coming out of this program are anticipated to control weight via a gene-controlling mechanism of action that is different from those of other products on the market.
WellGen’s Obesity Program is based upon the study of a proprietary gene panel comprised of carefully selected genes that are directed at affecting obesity. Functional food ingredients coming out of this program are anticipated to control weight via a gene-controlling mechanism of action that is different from those of other products on the market. Encouraged by animal studies that were completed in late 2005, WellGen anticipates beginning human clinical studies during 2006.
“We are pleased with the results that we are seeing and that our shareholders have confidence in WellGen’s ability to identify, develop and successfully commercialize consequential ingredients for the wellness market,” said David Evans, WellGen’s CEO.
Amphion Innovations plc, a company that builds and operates companies in the life sciences and medical technology markets, was lead investor in WellGen for this round. Richard Morgan, CEO of Amphion, said, “Nutrigenomics has the potential to play a formidable role in the nutrition industry and we expect WellGen to establish themselves as the market leader through their patented screening technologies. We’re excited about WellGen’s prospects and are happy to increase our investment.”
All content and features on this website are copyrighted with all rights reserved. The full details can be found in our privacy statement
